Please login to the form below

Article: Market access in Brazil

All eyes on Spinraza

Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil?

In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde (SUS). This is the first agreement in Brazil to include a risk-sharing model, in which the government only pays for the drug if there is improvement in the patient's health.

In a country where it typically takes years for innovative pharmaceutical products to be reimbursed in the public sector, manufacturers wishing to obtain market access for their products in Brazil will be watching this example closely to see how it plays out.

Read more on this article here: https://bit.ly/2qZ5HW1

1st November 2019

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Article
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma
Research Partnership
Infographic
Migraine market snapshot
Research Partnership
Webinar
Monitoring the impact of COVID-19 on the market access landscape
Research Partnership
Live webinar from Singapore
Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19
Research Partnership
Guide
UX research
Research Partnership
Article: Why pharma must trust the science of behaviour

Research Partnership